New and proprietary product enabling laboratories to analyze atmosphere-sensitive materials used to develop batteries, ...

DiagnaMed Holdings Corp. ("DiagnaMed" or the "Company") , a leading provider of innovative technology solutions for the cleantech and life sciences industries, is proud to announce a strategic ...

The strength and failure mechanisms of the composite sandwich beams in flatwise and edgewise configurations were investigated ... Despite the advantages of using these materials, there may be certain ...

Edgewise Therapeutics (EWTX) stock traded flat as Stifel launched its coverage with a Hold recommendation, indicating a ...

Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced key changes ...

We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the ...

We can readily understand why investors are attracted to unprofitable companies. For example, Edgewise Therapeutics (NASDAQ:EWTX) shareholders have done very well over the last year, with the share ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...

BOULDER, Colo.--(BUSINESS WIRE)--Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today provided recent corporate updates and highlighted upcoming ...

Presenting at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 1:30 p.m. PT (4:30 p.m. ET) - Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading muscle disease ...

Truist Financial analyst Srikripa Devarakonda maintained a Buy rating on Edgewise Therapeutics (EWTX – Research Report) today. The company’s shares closed yesterday at $25.33. Discover ...

Additionally, Edgewise is set to report significant data from its Phase 2 studies in Duchenne muscular dystrophy in the first half of 2025, which will further guide their Phase 3 planning.